{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:08:25Z","timestamp":1786990105278,"version":"build-2736575974"},"reference-count":32,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Immunology"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.humimm.2021.01.016","type":"journal-article","created":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T01:13:58Z","timestamp":1619745238000},"page":"574-580","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Abrogating biologics interference in flow cytometric crossmatching"],"prefix":"10.1016","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0199-3828","authenticated-orcid":false,"given":"Brian J.","family":"Franz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanne","family":"Petraroia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia D.","family":"Faust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tricia","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7018-2821","authenticated-orcid":false,"given":"Shari","family":"Smalls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7430-0757","authenticated-orcid":false,"given":"Candy","family":"Vongsavanh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisha","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Schmitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.humimm.2021.01.016_b0005","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1136\/jcp.2005.032300","article-title":"Biologic therapies: what and when?","volume":"60","author":"Johnston","year":"2007","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.humimm.2021.01.016_b0010","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jaad.2017.09.052","article-title":"Risk of infection in patients with atopic dermatitis treated with dupilumab: A meta-analysis of randomized controlled trials","volume":"78","author":"Fleming","year":"2018","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.humimm.2021.01.016_b0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2249.2010.04146.x","article-title":"How tumour necrosis factor blockers interfere with tuberculosis immunity","volume":"161","author":"Harris","year":"2010","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.humimm.2021.01.016_b0020","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med."},{"key":"10.1016\/j.humimm.2021.01.016_b0025","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.humimm.2021.01.016_b0030","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/QCO.0000000000000279","article-title":"Infections associated with the use of eculizumab: recommendations for prevention and prophylaxis","volume":"29","author":"Benamu","year":"2016","journal-title":"Current Opinion in Infectious Diseases"},{"key":"10.1016\/j.humimm.2021.01.016_b0035","doi-asserted-by":"crossref","unstructured":"A. Nixon, L. Ogden, A. Woywodt, A. Dhaygude, Infectious complications of rituximab therapy in renal disease, Clin Kidney J. 10 (2017) 455-60.","DOI":"10.1093\/ckj\/sfx038"},{"issue":"1","key":"10.1016\/j.humimm.2021.01.016_b0040","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1086\/504811","article-title":"Infectious Complications Associated with Alemtuzumab Use for Lymphoproliferative Disorders","volume":"43","author":"Martin","year":"2006","journal-title":"CLIN INFECT DIS"},{"issue":"6","key":"10.1016\/j.humimm.2021.01.016_b0045","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1016\/j.transproceed.2008.05.009","article-title":"Clinical Significance of a Positive Flow Crossmatch on the Outcomes of Cadaveric Renal Transplants","volume":"40","author":"Ilham","year":"2008","journal-title":"Transpl. Proc."},{"key":"10.1016\/j.humimm.2021.01.016_b0050","doi-asserted-by":"crossref","unstructured":"W.R. Mulley, J. Kanellis, Understanding crossmatch testing in organ transplantation: A case-based guide for the general nephrologist, Nephrology (Carlton). 16 (2011) 125-33.","DOI":"10.1111\/j.1440-1797.2010.01414.x"},{"issue":"2","key":"10.1016\/j.humimm.2021.01.016_b0055","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.humimm.2017.11.006","article-title":"Pronase independent flow cytometry crossmatching of rituximab treated patients","volume":"79","author":"Alheim","year":"2018","journal-title":"Hum. Immunol."},{"issue":"8","key":"10.1016\/j.humimm.2021.01.016_b0060","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.humimm.2004.06.001","article-title":"Pronase treatment facilitates alloantibody flow cytometric and cytotoxic crossmatching in the presence of rituximab","volume":"65","author":"Bearden","year":"2004","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.humimm.2021.01.016_b0065","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.humimm.2015.09.029","article-title":"Variable HLA expression on deceased donor lymphocytes: Not all crossmatches are created equal","volume":"76","author":"Badders","year":"2015","journal-title":"Hum Immunol."},{"issue":"4","key":"10.1016\/j.humimm.2021.01.016_b0070","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.humimm.2011.01.005","article-title":"Impact of pronase on flow cytometric crossmatch outcome","volume":"72","author":"Hetrick","year":"2011","journal-title":"Hum. Immunol."},{"issue":"2","key":"10.1016\/j.humimm.2021.01.016_b0075","doi-asserted-by":"crossref","first-page":"134","DOI":"10.4103\/0971-4065.159305","article-title":"Nonspecific positivity on the Luminex crossmatch assay for anti-human leukocyte antigen antibodies due to antibodies directed against the antibody coated beads","volume":"26","author":"Chacko","year":"2016","journal-title":"Indian J Nephrol"},{"issue":"5","key":"10.1016\/j.humimm.2021.01.016_b0080","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/j.transproceed.2013.02.038","article-title":"Comparative Performance Evaluation of a Donor-Specific Bead-Based Crossmatch Technique for the Detection of Donor-Specific Anti-HLA Antibodies in Heart Transplantation","volume":"45","author":"Chaidaroglou","year":"2013","journal-title":"Transpl. Proc."},{"key":"10.1016\/j.humimm.2021.01.016_b0085","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.humimm.2017.05.003","article-title":"Depletion of the chimeric drug Rituximab from biological samples","volume":"78","author":"Book","year":"2017","journal-title":"Hum Immunol."},{"key":"10.1016\/j.humimm.2021.01.016_b0090","doi-asserted-by":"crossref","unstructured":"M.S. Cragg, M.B. Bayne, A.L. Tutt, R.R. French, S. Beers, M.J. Glennie, et al., A new anti-idiotype antibody capable of binding rituximab on the surface of lymphoma cells, Blood. 104 (2004) 2540-2.","DOI":"10.1182\/blood-2004-05-1733"},{"key":"10.1016\/j.humimm.2021.01.016_b0095","doi-asserted-by":"crossref","unstructured":"M.D. Stegall, T. Diwan, S. Raghavaiah, L.D. Cornell, J. Burns, P.G. Dean, et al., Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients, Am J Transplant. 11 (2011) 2405-13.","DOI":"10.1111\/j.1600-6143.2011.03757.x"},{"issue":"2","key":"10.1016\/j.humimm.2021.01.016_b0100","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s40472-014-0012-y","article-title":"Acute Antibody-Mediated Rejection in Renal Transplantation: Current Clinical Management","volume":"1","author":"Schinstock","year":"2014","journal-title":"Curr Transpl Rep"},{"key":"10.1016\/j.humimm.2021.01.016_b0105","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1111\/j.1600-6143.2008.02441.x","article-title":"Alloantibody levels and acute humoral rejection early after positive crossmatch kidney transplantation","volume":"8","author":"Burns","year":"2008","journal-title":"Am J Transplant."},{"key":"10.1016\/j.humimm.2021.01.016_b0110","doi-asserted-by":"crossref","unstructured":"S.C. Jordan, N. Reinsmoen, A. Peng, C.H. Lai, K. Cao, R. Villicana, et al., Advances in diagnosing and managing antibody-mediated rejection, Pediatr Nephrol. 25 (2010) 2035-45; quiz 45-8.","DOI":"10.1007\/s00467-009-1386-4"},{"key":"10.1016\/j.humimm.2021.01.016_b0115","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1007\/s00467-014-2886-4","article-title":"Biologics in renal transplantation","volume":"30","author":"Grenda","year":"2015","journal-title":"Pediatr Nephrol."},{"key":"10.1016\/j.humimm.2021.01.016_b0120","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1009546","article-title":"Alemtuzumab induction in renal transplantation","volume":"364","author":"Hanaway","year":"2011","journal-title":"N Engl J Med."},{"key":"10.1016\/j.humimm.2021.01.016_b0125","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s40262-017-0573-x","article-title":"Review of the Clinical Pharmacokinetics and Pharmacodynamics of Alemtuzumab and Its Use in Kidney Transplantation","volume":"57","author":"van der Zwan","year":"2018","journal-title":"Clin Pharmacokinet."},{"key":"10.1016\/j.humimm.2021.01.016_b0130","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1600-6143.2007.02017.x","article-title":"Analysis of subcutaneous (SQ) alemtuzumab induction therapy in highly sensitized patients desensitized with IVIG and rituximab","volume":"8","author":"Vo","year":"2008","journal-title":"Am J Transplant."},{"issue":"Suppl 2","key":"10.1016\/j.humimm.2021.01.016_b0135","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/00001813-200211002-00002","article-title":"Mechanism of action of rituximab","volume":"13","author":"Cerny","year":"2002","journal-title":"Anticancer Drugs."},{"key":"10.1016\/j.humimm.2021.01.016_b0140","doi-asserted-by":"crossref","DOI":"10.4172\/2155-9899.1000152","article-title":"Insights into the Mechanisms of the Therapeutic Efficacy of Alemtuzumab in Multiple Sclerosis","volume":"4","author":"Freedman","year":"2013","journal-title":"J Clin Cell Immunol."},{"key":"10.1016\/j.humimm.2021.01.016_b0145","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.humimm.2016.04.014","article-title":"Flow cytometry crossmatch reactivity with pronase-treated T cells induced by non-HLA autoantibodies in human immunodeficiency virus-infected patients","volume":"77","author":"Szewczyk","year":"2016","journal-title":"Hum Immunol."},{"key":"10.1016\/j.humimm.2021.01.016_b0150","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jim.2010.05.009","article-title":"Validation of an ELISA for the determination of rituximab pharmacokinetics in clinical trials subjects","volume":"360","author":"Hampson","year":"2010","journal-title":"J Immunol Methods."},{"key":"10.1016\/j.humimm.2021.01.016_b0155","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/j.1432-2277.1995.tb01558.x","article-title":"The use of pronase-digested human leukocytes to improve specificity of the flow cytometric crossmatch","volume":"8","author":"Lobo","year":"1995","journal-title":"Transpl Int."},{"key":"10.1016\/j.humimm.2021.01.016_b0160","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1432-2277.2002.tb00108.x","article-title":"Improved specificity and sensitivity when using pronase-digested lymphocytes to perform flow-cytometric crossmatch prior to renal transplantation","volume":"15","author":"Lobo","year":"2002","journal-title":"Transpl Int."}],"container-title":["Human Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0198885921000379?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0198885921000379?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T11:53:54Z","timestamp":1759319634000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0198885921000379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S0198885921000379"],"URL":"https:\/\/doi.org\/10.1016\/j.humimm.2021.01.016","relation":{},"ISSN":["0198-8859"],"issn-type":[{"value":"0198-8859","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Abrogating biologics interference in flow cytometric crossmatching","name":"articletitle","label":"Article Title"},{"value":"Human Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humimm.2021.01.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}